Journey Biosciences adds two accomplished independent directors with deep roots in the diabetes industry to its board to coincide with its recent commercial launch
Journey Biosciences adds two accomplished independent directors with deep roots in the diabetes industry to its board to coincide with its recent commercial launch |
[28-October-2021] |
LEBANON, N.H., Oct. 28, 2021 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company who recently announced the launch of its NaviDKD proactive diagnostic screening technology for high risk kidney complications associated with Diabetes, is pleased to announce it has appointed two independent non-executive directors with a proven track record of advocacy in the diabetes community to its board of directors, Greg Dooley and Gordie Nye. Journey Biosciences adds two accomplished independent directors with deep roots in the diabetes industry to its board. “Greg and Gordie both have impressive experiences in consumer products and healthcare organizations,” said Adam Graybill, President and CEO of Journey Biosciences. “They bring a deep, meaningful connection to the diabetes community from current and past experiences that will be extremely valuable as we launch NaviDKD in the U.S.” Additional information about the new directors can be found below: Greg Dooley Gordie Nye About Journey Biosciences, Inc. Journey Biosciences’ mission is to fundamentally improve diabetes care by providing health care professionals and people with diabetes the necessary diagnostic screening tools to proactively manage and prevent high risk complications associated with diabetes. KNOW YOUR RISKS. CHANGE YOUR LIFE. Learn more about Journey Biosciences by visiting www.journeybio.life. View original content to download multimedia:https://www.prnewswire.com/news-releases/journey-biosciences-appoints-greg-dooley-and-gordie-nye-to-its-board-of-directors-301410960.html SOURCE Journey Biosciences, Inc. |